Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Longeveron Receives FDA Fast Track Designation For Lomecel-B For Mild Alzheimer's Disease; Second Designation Following RMAT Designation On July 9, 2024

Author: Benzinga Newsdesk | July 17, 2024 08:01am

Phase 2a Data To Be Presented At Alzheimer's Association International Conference; Lomecel-B Is An Allogeneic Investigational Cellular Therapy Also Evaluated For Aging-Related Frailty And Hypoplastic Left Heart Syndrome

Posted In: LGVN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist